Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Evert Luwel"'
Autor:
Wilfried Mullens, Pieter Martens, Omid Forouzan, Jeroen Dauw, Jan Vercammen, Evert Luwel, Wendy Ceyssens, Veerle Kockaerts, Koen Ameloot, Matthias Dupont
Publikováno v:
ESC Heart Failure, Vol 7, Iss 5, Pp 2071-2073 (2020)
Aims To explore the effects of dapagliflozin on congestion through CardioMEMS (Abbott Inc., Atlanta, USA) and Cordella™ pulmonary artery Sensor (Endotronix Inc., Lisle, Il, USA) devices, which are implantable systems that provide real‐time remote
Externí odkaz:
https://doaj.org/article/3ba4d7ef09dc4612b88950724ff5ae2b
Autor:
Evert Luwel, Pieter Martens, Peter Potargent, Jan Vercammen, Wendy Ceyssens, Wilfried Mullens, Herwig Van Aerde, Monique Renaers, Matthias Dupont, Linda Jacobs
Publikováno v:
ESC Heart Failure. 5:562-569
AIMS In patients with palliative end-stage heart failure, interventions that could provide symptomatic relief and prevent hospital admissions are important. Ambulatory continuous intravenous inotropes have been advocated by guidelines for such a purp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdddc9f9c07e05ef8e254ce82729af00
https://doi.org/10.1002/ehf2.12248
https://doi.org/10.1002/ehf2.12248
Autor:
Maximo Rivero-Ayerza, Jan Vercammen, Dieter Nuyens, Wilfried Mullens, Evert Luwel, Pieter Martens, Wendy Ceyssens, Matthias Dupont, Hugo Van Herendael
Publikováno v:
Clinical research in cardiology : official journal of the German Cardiac Society. 108(10)
Sacubitril/valsartan reduced the occurrence of sudden cardiac death in the PARADIGM-HF trial. However, limited information is available about the mechanism. Heart failure (HF)-patients receiving sacubitril/valsartan for a class-I indication equipped
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d9279cdc8ac63beb3f209c7032f75bb
https://pubmed.ncbi.nlm.nih.gov/30788621
https://pubmed.ncbi.nlm.nih.gov/30788621